Healthcare tech company GoodRx (NASDAQ: GDRX) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, but sales fell by 4.4% year on year to $194 million. The company’s full-year revenue guidance of $775 million at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.07 per share was in line with analysts’ consensus estimates.

Is now the time to buy GoodRx? Find out by accessing our full research report, it’s free.

Company Overview

Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ: GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Regrettably, GoodRx’s sales grew at a mediocre 6.4% compounded annual growth rate over the last five years. This fell short of our benchmark for the healthcare sector and is a rough starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. GoodRx’s recent performance shows its demand has slowed as its revenue was flat over the last two years.

This quarter, GoodRx’s revenue fell by 4.4% year on year to $194 million but beat Wall Street’s estimates by 5.1%.

Looking ahead, sell-side analysts expect revenue to decline by 2% over the next 12 months, a slight deceleration versus the last two years. This projection doesn't excite us and implies its products and services will face some demand challenges.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Adjusted Operating Margin

Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.

GoodRx has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 24.6%.

Looking at the trend in its profitability, GoodRx’s adjusted operating margin decreased by 4.9 percentage points over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.

In Q1, GoodRx generated an adjusted operating margin profit margin of 20.3%, down 5.2 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

GoodRx’s flat EPS over the last five years was below its 6.4% annualized revenue growth. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.

We can take a deeper look into GoodRx’s earnings to better understand the drivers of its performance. As we mentioned earlier, GoodRx’s adjusted operating margin declined by 4.9 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q1, GoodRx reported adjusted EPS of $0.07, down from $0.09 in the same quarter last year. This print missed analysts’ estimates. Over the next 12 months, Wall Street expects GoodRx’s full-year EPS of $0.33 to grow 1%. This is unusual as its revenue and operating margin are anticipated to fall, signaling the increase likely stems from "below-the-line" items such as taxes.

Key Takeaways from GoodRx’s Q1 Results

We were impressed by how significantly GoodRx blew past analysts’ revenue expectations this quarter. We were also glad its full-year revenue guidance slightly exceeded Wall Street’s estimates. On the other hand, its EPS was in line. Overall, we think this was a decent quarter with some key metrics above expectations. The stock remained flat at $2.57 immediately after reporting.

So should you invest in GoodRx right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).